Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
ORIGINAL E n d o c r i n e C a r e — B r i e f ARTICLE R e p o r t Lipodystrophy in Patients with Acromegaly Receiving Pegvisomant Vivien S. Bonert, Laurence Kennedy, Stephan Petersenn, Ariel Barkan, John Carmichael, and Shlomo Melmed Department of Medicine (V.S.B., J.C., S.M.), Cedars-Sinai Medical Center, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California 90048; Department of Medicine (L.K.), University of Florida, Gainesville, Florida 32610; Division of Endocrinology (S.P.), Medical Center, University of Duisburg-Essen, 47048 Duisburg, Germany; and Department of Neurosurgery and Division of Metabolism, Endocrinology, and Diabetes (A.B.), University of Michigan Medical Center, Ann Arbor, Michigan 48105 Context: Pegvisomant, a GH receptor antagonist, suppresses serum IGF-I levels into the normal range in more than 95% of patients with acromegaly. Documented side effects in the initial registration studies included headache, injection-site reactions, flu-like syndrome, and reversible elevation of hepatic enzymes. Objective: We report seven patients with acromegaly treated with pegvisomant who developed lipodystrophy at the site of injection (anterior abdominal wall, thigh, buttock, and upper arm). This side effect resulted in discontinuation of pegvisomant in four patients, with subsequent regression of lipohypertrophy. Subjects: Six female and one male patient with acromegaly, aged 24 –59 yr, are reported. All patients had undergone prior transsphenoidal surgery, and four received subsequent radiotherapy. Four patients had been treated with maximal doses of somatostatin analogs with partial suppression of IGF-I levels before initiation of pegvisomant therapy. Pegvisomant suppressed IGF-I levels into the normal range in five of seven subjects, before discontinuation of the drug. Two of seven patients received pegvisomant as first-line medical therapy, without prior somatostatin analog treatment, and one received combination therapy with a long-acting somatostatin analog and weekly pegvisomant injections. One patient experienced an erythematous superficial injection-site reaction that responded to application of steroid cream before the onset of lipohypertrophy. Conclusions: We report seven patients with acromegaly who developed lipohypertrophy at the pegvisomant injection site. Pegvisomant was discontinued due to dissatisfaction with lipohypertrophy by four patients. Lipohypertrophy regressed in all patients when the medication was discontinued. Lipohypertrophy recurred when two patients were rechallenged with pegvisomant. Patients receiving pegvisomant should undergo frequent examination of injection sites for lipohypertrophy. (J Clin Endocrinol Metab 93: 3515–3518, 2008) M edical treatment of patients with acromegaly is indicated as either primary or adjunctive therapy after pituitary tumor resection with or without radiation. Somatostatin analogs bind to pituitary tumor somatostatin receptors and suppress tumor GH secretion with normal serum IGF-I levels achieved in more than 65% of patients. These analogs have been the mainstay of effective and well tolerated medical therapy for acro- megaly for 20 yr (1). Most frequently reported adverse events of these generally safe peptide analogs include transient, mild gastrointestinal side effects including gas, abdominal cramps, diarrhea, and steatorrhea. Twenty percent of patients develop gallbladder sludge, of whom 20% develop frank asymptomatic gallstones. Injection-site reactions, bradycardia, and alopecia occur rarely (1). 0021-972X/08/$15.00/0 Abbreviations: LAR, Long-acting release; MRI, magnetic resonance imaging. Printed in U.S.A. Copyright © 2008 by The Endocrine Society doi: 10.1210/jc.2008-0833 Received April 17, 2008. Accepted June 26, 2008. First Published Online July 8, 2008 J Clin Endocrinol Metab, September 2008, 93(9):3515–3518 jcem.endojournals.org 3515 3516 Bonert et al. Lipodystrophy and Pegvisomant J Clin Endocrinol Metab, September 2008, 93(9):3515–3518 TABLE 1. Case Age (yr) Gender Year of diagnosis TSS (date) 1 2 3 4 22 50 28 46 F M F F 1999 2001 1998 2002 1999 2001 1998 2003 5 6 7 46 56 36 F F F 1999 2003 1997 1999 2004 1997 RT (date) Hormone replacement, [drug (date)] External beam (1999) Stereotactic radiosurgery (2005) Levothyroxine (2000) RT (2006) Levothyroxine, hydrocortisone (2000) Levothyroxine (2000) ␥-Knife (2001) Levothyroxine (Continues) Pegvisomant, a pegylated GH analog, competes with endogenous GH ligand and functions as a peripheral GH receptor antagonist, blocking hepatic IGF-I production (2). Ninety-seven percent of patients with acromegaly achieved normal serum IGF-I levels when treated with pegvisomant for 12 months or longer (3). Pegvisomant was approved by the U.S. Food and Drug Administration in 2004, and long-term surveillance is currently underway to monitor drug safety. Although serum GH levels initially increase after initiation of therapy and then plateau after about 2 wk (2), pegvisomant is detected in conventional GH assays, which could result in falsely elevated estimation of serum GH concentrations. Adverse effects including headache (26% of patients), injection-site reactions (11%), pain (23%), and flulike syndrome (21%) were reported in the initial 12-wk pegvisomant study (2). Pegvisomant therapy enhances insulin sensitivity, improves glucose tolerance (4), and lowers glycosylated hemoglobin levels, suggesting a beneficial effect of the drug on glucose homeostasis in acromegaly patients both with and without diabetes (5). Although increased pituitary tumor size due to disrupted IGF-I inhibitory feedback on the pituitary is a potential adverse effect of pegvisomant therapy, stable tumor volumes were reported in 131 patients treated for 12 months (3). Reversible increased serum hepatic transaminase levels were documented in two of 112 patients treated with pegvisomant for 3 months (2). Drug-induced hepatitis was observed in a patient receiving combined treatment with pegvisomant and octreotide; hepatic enzymes returned to normal after discontinuation of pegvisomant and recurred after drug rechallenge (6). A recent surveillance study reported discontinuing pegvisomant treatment in six of 142 patients because of elevated transaminases (7). We report here reversible focal lipohypertrophy developing shortly after initiation of pegvisomant therapy in seven patients with acromegaly. Patients Clinical history Six female and one male patient (aged 24 –59 yr) with acromegaly, managed between 1997 and 2008 (Table 1), underwent transsphenoidal pituitary tumor resection, and four then received radiotherapy. Five pa- tients subsequently received somatostatin analog therapy with suboptimal control of IGF-I levels and were then treated with sc pegvisomant injections (10 – 40 mg/d). Pegvisomant was initiated directly after surgery in two patients without prior somatostatin analog therapy. One patient received monthly octreotide long-acting release (LAR) 30 mg together with weekly pegvisomant 15 mg sc. Lipohypertrophy developed 1–12 wk after initiating pegvisomant therapy. A total of 60 patients have received pegvisomant therapy in our centers. Patient 1 developed extensive, firm anterior abdominal wall swelling that interfered with her ability to dress with her jeans. She had also injected pegvisomant into her thighs and buttocks and noted swelling at these sites. On discontinuation of pegvisomant, lipohypertrophy regressed with minimal residual swelling. Nine months later, pegvisomant therapy was reinitiated to suppress elevated IGF-I levels. Pegvisomant 10 mg sc was initially injected every 3 d into the buttock, and after a month, increased to alternate-day injections. After 5 months, firm nontender bilateral buttock swelling developed. A suboptimal IGF-I response necessitated increasing the pegvisomant dose to 30 mg on alternate days with continued resistance of IGF-I levels. Buttock lipodystrophy persisted, and she elected to discontinue pegvisomant whereupon the lipodystrophy regressed over 2 months. Patient 2 developed anterior abdominal wall lipohypertrophy within a week of starting 10 mg daily pegvisomant administered in the abdomen. Injection site was switched to the thighs with regression of anterior abdominal wall lipohypertrophy, but swelling developed at the thigh injection sites. Pituitary-directed stereotaxic radiosurgery resulted in normal serum IGF-I levels, and pegvisomant was discontinued. Two months later, IGF-I levels increased, pegvisomant therapy was restarted, and lipohypertrophy recurred at the abdominal injection site. Patient 3 received pegvisomant (20 mg/d), rotating the injection site between the thighs and arms, but developed swellings at the arm and thigh injection sites within 3 months of initiating pegvisomant therapy. Because the swellings were unsightly, the patient elected to discontinue pegvisomant after 12 months, despite attaining normal serum IGF-I levels, and the swellings slowly regressed over the subsequent 6 months. Patient 4 started pegvisomant therapy after transsphenoidal surgery. She had received preoperative somatostatin analog therapy with poor control of serum IGF-I levels. Pegvisomant was injected into the anterior abdominal wall, and the dose was increased to 40 mg/d. She experienced a dramatic increase in abdominal fat over the 3-month treatment period, beginning a few weeks after initiation of injections. Abdominal magnetic resonance imaging (MRI) at the level of the umbilicus showed increased sc fat tissue thickness. Patient 5 developed lipohypertrophy of the abdomen while receiving combination therapy with octreotide LAR and weekly pegvisomant injections. She received LAR 30 mg monthly into the buttocks for 3 months, with partial suppression of IGF-I levels from 849 ng/ml J Clin Endocrinol Metab, September 2008, 93(9):3515–3518 jcem.endojournals.org 3517 TABLE 1. (Continued) SRIF analog therapy Starting IGF-I [ng/ml (date)] Maximum dose (mg) 1280 (1999) LAR 40 1135 (1998) (nl, ⬍380) 616 (2002) 849 (2006) (nl, 60 –304) LAR 20 LAR 30 LAR 30 653 (2001) (nl, 114 – 492) LAR 30 Pegvisomant therapy Nadir IGF-I (ng/ml) Starting IGF-I [ng/ml (date)] 595 (2002) (nl, ⬍492) 440 (2004) (nl, ⬍360) 970 1380 (1998) (nl, ⬍380) 600 712 (2003) (90 –360) 479 (2006) (nl, 88 –249) 479 (nl, 88 –249) 562 (2005) (nl, 71–290) 369 (nl, 115–307) 518 (2006) (nl, 109 –284) 369 (nl, 115–307) Maximum dose (mg/d) 10 15 20 40 15 10 15 Nadir IGF-I (ng/ml) Imaging 320 (nl, ⬍492) 111 (nl, ⬍360) 150 (nl, ⬍380) 379 (90 –360) MRI abdomen 410 (nl, 88 –249) 110 (nl, 71–290) MRI abdomen 142 (nl, 109 –284) F, Female; M, male; nl, normal; RT, radiotherapy; SRIF, somatostatin; TSS, transsphenoidal surgery. (60 –304) to 479 ng/ml (88 –249). Subcutaneous weekly pegvisomant (10 mg) was injected in her thighs. After a month, serum IGF-I levels were 330 ng/ml (88 –249), and the pegvisomant dose increased to 15 mg weekly. Injection sites were rotated between thigh and abdomen. After 2 wk on the increased pegvisomant dose, lipohypertrophy of the anterior abdominal wall and thighs developed. Pegvisomant was discontinued. Patient 6 (Fig. 1) noticed swelling of the anterior abdominal wall 4 months after starting pegvisomant (10 mg/d), rotating injection sites around the umbilicus. The injection site was changed to the thighs with partial resolution of abdominal lipodystrophy. She did not develop thigh lipodystrophy and elected to continue pegvisomant therapy. Patient 7 developed erythema, pruritus, and injection-site swelling 3 wk after starting pegvisomant (15 mg daily) injected into rotating sites around the umbilicus. Symptoms resolved with local application of 1% hydrocortisone cream. Five weeks later, she experienced anterior abdominal wall swelling and then injected the drug into her thighs, buttocks, and upper arms, with subsequent swelling in all these areas. Despite no further injections of pegvisomant into the anterior abdominal wall, the lipohypertrophy persists. She continues to inject pegvisomant into the buttocks, arms, and legs, and serum IGF-I levels are normal. Patients 5 and 7 experienced other side effects while receiving pegvisomant, including persistent pituitary tumor enlargement on serial MRI examinations and erythematous superficial injection-site reaction that responded to topical steroid cream before onset of lipohypertrophy. Discussion Two classes of drugs available to manage patients with acromegaly and GH oversecretion (1) include somatostatin analogs acting primarily at the level of the pituitary tumor and pegvisomant acting at the periphery to block GH action. Both these therapies are efficacious and generally safe, and their use is determined by individual patient clinical needs. Lipodystrophy, a disorder of adipose tissue involving selective loss or gain of fat cells can be localized and acquired in association with parenteral drug administration (8). Localized adipose tissue changes secondary to drug administration result in depressed skin areas (lipoatrophy) or areas of fat overgrowth (lipohypertrophy). Before the advent of recombinant insulin, lipoatrophy was commonly associated with insulin administration, likely attributable to a local immune reaction to crystals of impure insulin preparations (9). Localized lipoatrophy has been reported as a complication of im injection of benzathine penicillin (10, 11) and steroids (11). After administration of sc octreotide for 2– 6 yr (12), three female patients with acromegaly developed injection-site lipoatrophy (upper arms, thighs, and abdomen). After therapy was changed to im octreotide LAR injection, lipoatrophy regressed in one patient after 12 months but persisted after 8 and 12 months of therapy in two patients. Chronic exogenous GH administration to GH-deficient children results in a relative increase in gluteal relative to abdominal sc fat, presumably due to decreased sensitivity to the antilipolytic action of insulin (13). Focal lipohypertrophy of the anterior abdominal wall associated with pegvisomant has been reported in two patients with acromegaly (14). A biopsy of the mass performed in one patient (15) showed normal sc adipose tissue devoid of inflammatory cells or fat necrosis. Increased fat mass and decreased lean body mass evident in GH-deficient adults (16) is reversible with GH administration (16), highlighting the important role GH plays in maintenance of adult body composition. Acute GH administration promotes FIG. 1. Anterior abdominal wall lipohypertrophy in patient 6 at 4 months after injection of pegvisomant. lipolysis and decreases adiposity (17). FurAbdominal MRI shows increased sc fat in the region of clinical lipohypertrophy in the patient (arrow). 3518 Bonert et al. Lipodystrophy and Pegvisomant thermore, GH also regulates adipocyte differentiation, although discrepant results have been reported between preadipocyte cell lines and primary adipocyte cultures (18). The average size and lipid content of sc adipocytes in GH-deficient patients is greater than in GH-replete subjects, and GH therapy decreases both adipocyte size and lipid content in these patients (19). Our observations suggest that local antagonism of GH action by pegvisomant may result in abrogated GH signaling at the injection site, with unopposed insulin effects resulting in lipogenesis and increased local adiposity. Interestingly, six of the seven patients experiencing lipohypertrophy were female, despite the fact that the gender ratio is approximately 50:50 in acromegaly (20). Furthermore, the three reported patients with lipohypertrophy associated with octreotide were female (15) as well as one of the two previously reported cases of lipohypertrophy associated with pegvisomant (16). The observed female preponderance may be attributable to a greater female accumulation of sc adipose tissue or may be a gender-specific adipocyte response. Localized lipohypertrophy developed at the site of injection (anterior abdominal wall, upper arms, thigh, and buttock) in seven patients from 1–12 wk after initiating therapy. Four patients moved the injection site, and all experienced lipohypertrophy at the new site of injection. Four patients discontinued pegvisomant therapy, because the lipohypertrophy was unsightly, and experienced regression of the swelling. Two patients were rechallenged with pegvisomant and developed recurrent lipohypertrophy. Whether the development of lipohypertrophy is related to the dose or frequency of pegvisomant injection has not been determined. However, lipohypertrophy was apparent at lower doses of pegvisomant and even during combination with somatostatin analog in one patient. Potential antagonism of the effects of GH on local adipocyte lipid metabolism could result in this newly recognized side effect. Although lipohypertrophy does not appear to have major detrimental clinical implications, it is a significant side effect, because patient dissatisfaction or discomfort results from pegvisomant therapy. Patients should be instructed to diligently rotate GH injection sites. Injection sites of patients with acromegaly receiving pegvisomant should be monitored for early signs of lipohypertrophy and patients advised that regression is likely after drug discontinuation. Acknowledgments Address all correspondence and requests for reprints to: Vivien Bonert, M.D., Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048. E-mail: [email protected]. Disclosure Statement: V.S.B., J.C., and S.M. have nothing to declare. A.B. and S.P. consult for Pfizer. A.B., S.P., and L.K. have received lecture fees from Pfizer. J Clin Endocrinol Metab, September 2008, 93(9):3515–3518 References 1. Melmed S 2006 Medical progress: acromegaly. N Engl J Med 355:2558 –2573 2. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171–1177 3. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO 2001 Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754 –1759 4. Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP, Trainer PJ 2003 Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 149:521–527 5. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML 2005 Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 90:5684 –5691 6. Feenstra J, van Aken MO, de Herder WW, Feelders RA, van der Lely AJ 2006 Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. Eur J Endocrinol 154:805– 806 7. Biering H, Saller B, Bauditz J, Pirlich M, Rudolph B, Johne A, Buchfelder M, Mann K, Droste M, Schreiber I, Lochs H, Strasburger CJ 2006 Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur J Endocrinol 154:213–220 8. Garg A 2000 Lipodystrophies. Am J Med 108:143–152 9. Reeves WG, Allen BR, Tattersall RB 1980 Insulin-induced lipoatrophy: evidence for an immune pathogenesis. BMJ 280:1500 –1503 10. Kayikcioglu A, Akyurek M, Erk Y 1996 Semicircular lipoatrophy after intragluteal injection of benzathine penicillin. J Pediatr 129:166 –167 11. Dahl PR, Zalla MJ, Winkelmann RK 1996 Localized involutional lipoatrophy: a clinicopathologic study of 16 patients. J Am Acad Dermatol 35:523–528 12. Atmaca A, Erbas T 2005 Lipoatrophy induced by subcutaneous administration of octreotide in the treatment of acromegaly. Exp Clin Endocrinol Diabetes 113:340 –343 13. Rosenbaum M, Gertner JM, Leibel RL 1989 Effects of systemic GH administration on regional adipose tissue distribution and metabolism in GH-deficient children. J Clin Endocrinol and Metab 69:1274 –1281 14. Maffei P, Martini C, Pagano C, Sicolo N, Corbetti F 2006 Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant. Ann Intern Med 145:310 –312 15. Marazuela M, Dauden E, Ocon E, Moure D, Nattero L 2007 Pegvisomantinduced lipohypertrophy: report of a case with histopathology. Ann Intern Med 147:741–743 16. Salomon F, Cuneo RC, Hesp R, Sonksen PH 1989 The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 321:1797–1803 17. Gotherstrom G, Bengtsson BA, Bosaeus I, Johannsson G, Svensson J 2007 A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J Clin Endocrinol Metab 92:1442–1445 18. Nam SY, Lobie PE 2000 The mechanism of effect of growth hormone on preadipocyte and adipocyte function. Obes Rev 1:73– 86 19. Brook CG 1973 Effect of human growth hormone treatment on adipose tissue in children. Arch Dis Childhood 48:725–728 20. Holdaway IM, Rajasoorya C 1999 Epidemiology of acromegaly. Pituitary 2:29 – 41